<DOC>
	<DOCNO>NCT00604760</DOCNO>
	<brief_summary>To establish proof concept MEM 3454 , use add-on pharmacotherapy , safe effective treatment patient cognitive impairment associate schizophrenia ( CIAS ) .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy MEM 3454 Adjunctive Treatment Combination With Preexisting Antipsychotic Patients With Cognitive Impairment Associated With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis schizophrenia ( subtype ) , assess use structure interview . At least one month dose antipsychotic medication . Clinically stable , judged investigator , nonacute phase least 12 week . Able provide inform consent . Fluent English . Smokers nonsmoker . First 3 year schizophrenia diagnosis . Current risk suicide , history suicidal behavior within last 6 month . Hospitalized psychiatric symptom past 3 month . Other psychiatric diagnosis . Substance abuse/dependence ( nicotine caffeine ) within last 6 month accord . Nicotine replacement therapy , smoke cessation medication remedy , include Varenicline ( Chantix ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>